NASDAQ:OXFD Oxford Immunotec Global (OXFD) Stock Price, News & Analysis → See this before next week's Fed meeting (From Stansberry Research) (Ad) Free OXFD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$21.99▼$21.9950-Day Range$21.88▼$21.9952-Week Range$8.37▼$23.11VolumeN/AAverage Volume1.10 million shsMarket Capitalization$570.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Oxford Immunotec Global alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Oxford Immunotec Global Stock (NASDAQ:OXFD)Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.Read More Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. OXFD Stock News HeadlinesApril 24, 2024 | benzinga.comDecoding 6 Analyst Evaluations For Oxford IndustriesApril 18, 2024 | msn.comDiscover what Oxford International College Brighton has to offerApril 25, 2024 | Stansberry Research (Ad)See this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) April 3, 2024 | bbc.co.ukOxford man charged with five sexual assaults in one nightMarch 29, 2024 | msn.comDiagnostics startup Noze awarded $1.8m grant for World Tuberculosis DayMarch 18, 2024 | msn.comOxford ranked top city in England for recycling in new government figuresMarch 9, 2024 | msn.comOxford University held training sessions for Chinese doctors accused of harvesting organsMarch 2, 2024 | msn.comOxford LTNs: Oxford University research project to mediate debateApril 25, 2024 | Stansberry Research (Ad)See this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) February 14, 2024 | msn.comOxford Technology Park welcomes engineering services providerFebruary 7, 2024 | cbsnews.comOxford High School shootingFebruary 6, 2024 | cbsnews.comOxford High SchoolJanuary 18, 2024 | msn.comHMV is planning to shake up retail with Oxford Street comebackJanuary 9, 2024 | news.yahoo.comOxford main road reopens as county battles floodsJanuary 5, 2024 | msn.comTechnology firm set for move to Oxford Technology ParkDecember 28, 2023 | msn.comIn demand: How Oxford Street started to get its groove back in 2023November 29, 2023 | msn.comOxford Pride and Oxford University join to commemorate World AIDS DayNovember 26, 2023 | seekingalpha.comOxford Industries: Undervalued Company With Solid BrandNovember 24, 2023 | forbes.comHMV Makes Historic Return To Its Original Oxford Street HomeNovember 14, 2023 | cbsnews.comOxford TownshipSeptember 26, 2023 | msn.comPetrol prices on the rise: Where to find the cheapest fuel in OxfordSeptember 26, 2023 | businesswire.comOxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch ® Prostate Screening Blood Test to Men With Prostate Cancer RiskSeptember 24, 2023 | msn.comLatest milestone for Oxfordshire science park - as Oxford pipped by Cambridge againSeptember 11, 2023 | msn.comBMW announces £600m package for Oxford EV plantAugust 31, 2023 | benzinga.comOxford Science Enterprises Appoints Ed Bussey as Chief Executive OfficerAugust 29, 2023 | msn.comOxford University spinouts venture picks ex-diplomat as new chiefAugust 15, 2023 | benzinga.comOxford Treatment Center at Forefront of Equine-Assisted Therapy Research for AddictionSee More Headlines Receive OXFD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Immunotec Global and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryN/A Current SymbolNASDAQ:OXFD CUSIPN/A CIK1586049 Webwww.oxfordimmunotec.com Phone44-0-12-3544-2780FaxN/AEmployees273Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,810,000.00 Net Margins-30.51% Pretax MarginN/A Return on Equity-8.39% Return on Assets-7.63% Debt Debt-to-Equity RatioN/A Current Ratio15.96 Quick Ratio14.85 Sales & Book Value Annual Sales$73.71 million Price / Sales7.75 Cash Flow$0.02 per share Price / Cash Flow1,408.78 Book Value$8.08 per share Price / Book2.72Miscellaneous Outstanding Shares25,962,000Free FloatN/AMarket Cap$570.90 million OptionableNot Optionable Beta1.42 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Peter Wrighton-Smith (Age 47)CEO & Exec. Director Comp: $1.11MMr. Matthew T.E. McLaughlin (Age 44)Chief Financial Officer Comp: $527.45kMs. Janet Louise Kidd (Age 51)Gen. Counsel & Company Sec. Dr. Peter Edwardson (Age 59)Sr. VP & Head of Blood Screening Mr. Jeff R. Schroeder (Age 60)Pres, Strategic Accounts Key CompetitorsAchieve Life SciencesNASDAQ:ACHVAspira Women's HealthNASDAQ:AWHImmuCellNASDAQ:ICCCMeridian BioscienceNASDAQ:VIVOMyriad GeneticsNASDAQ:MYGNView All Competitors OXFD Stock Analysis - Frequently Asked Questions How were Oxford Immunotec Global's earnings last quarter? Oxford Immunotec Global PLC (NASDAQ:OXFD) announced its quarterly earnings data on Tuesday, November, 3rd. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.01). The company earned $19.44 million during the quarter, compared to analysts' expectations of $18.58 million. Oxford Immunotec Global had a negative net margin of 30.51% and a negative trailing twelve-month return on equity of 8.39%. What is Peter Wrighton-Smith's approval rating as Oxford Immunotec Global's CEO? 39 employees have rated Oxford Immunotec Global Chief Executive Officer Peter Wrighton-Smith on Glassdoor.com. Peter Wrighton-Smith has an approval rating of 75% among the company's employees. What other stocks do shareholders of Oxford Immunotec Global own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include Dynavax Technologies (DVAX), AbbVie (ABBV), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Immunomedics (IMMU), Intel (INTC), Iovance Biotherapeutics (IOVA), Inovio Pharmaceuticals (INO) and Netflix (NFLX). This page (NASDAQ:OXFD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Immunotec Global PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
